MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease typ...
MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A
About this item
Full title
Author / Creator
Rocha, Agostinho G. , Franco, Antonietta , Krezel, Andrzej M. , Rumsey, Jeanne M. , Alberti, Justin M. , Knight, William C. , Biris, Nikolaos , Zacharioudakis, Emmanouil , Janetka, James W. , Baloh, Robert H. , Kitsis, Richard N. , Mochly-Rosen, Daria , Townsend, R. Reid , Gavathiotis, Evripidis and Dorn, Gerald W.
Publisher
United States: The American Association for the Advancement of Science
Journal title
Language
English
Formats
Publication information
Publisher
United States: The American Association for the Advancement of Science
Subjects
More information
Scope and Contents
Contents
Charcot-Marie-Tooth disease type 2A (CMT2A) is a rare, inherited neurodegenerative condition. Affected individuals develop severe progressive muscle weakness, motor deficits, and peripheral neuropathy. Although defects in the gene encoding mitofusin 2 (MFN2) are known to cause CMT2A, the disease remains incurable. Rocha
et al.
identified spec...
Alternative Titles
Full title
MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6109362
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6109362
Other Identifiers
ISSN
0036-8075,1095-9203
E-ISSN
1095-9203
DOI
10.1126/science.aao1785
